Welcome back to Infinite Health, where today’s episode dives into sweeping changes in cardiovascular medicine and what they mean for you. The conversation focused on breakthrough developments in cholesterol-lowering therapies, emerging tests for heart disease risk, and practical strategies for managing elevated lipoprotein(a), or Lp. One concept discussed was the advent of the first oral PCSK9 inhibitor and updates on drugs targeting previously “untreatable” risk factors. A key theme that emerged was the importance of looking beyond just the numbers why lowering a biomarker doesn’t always translate to saved lives, and how new guidelines are pushing for more personalized care. The discussion explored genetic risk, evidence-based drug choices, and a step-by-step approach to navigating confusing lab results. Whether you’re a longtime patient, clinician, or just curious about staying heart-healthy, this episode delivers clarity, myth-busting, and action steps rooted in the latest science.

00:00 Introducing Dr. Moran's background

05:10 Explaining ApoB and new guidelines

07:48 Blocking PCSK9 to reduce LDL

11:01 Macrocyclic peptide cholesterol treatment

16:38 2026 guidelines recommend lipoprotein testing

17:40 Discussing Lp(a) treatment trials

21:17 Negative trial results for new drugs

25:27 Understanding heart disease risk factors

29:45 Understanding aortic valve stenosis

30:52 Understanding high Lp levels

36:49 Sharing the episode with others

37:35 Educational purpose and medical disclaimers

www.infinitehealthpodcast.com

www.tophealth.care